Science Articles from the Newsletter
August 2012 (View e-newsletter on www.GISTNews.org)
Vol. 13, No. 4
· Identifying Novel Treatment Options by Defining Molecular Mechanisms
· Several Clinical Trials Updated at ASCO
· MSKCC Opens New Immunotherapy Trial for GIST
June 2012 (View e-newsletter on www.GISTNews.org)
Vol. 13, No. 3
· Guidelines Proposed for Pediatric GIST
April 2012 (View e-newsletter on www.GISTNews.org)
Vol. 13, No. 2
· Cellular Origin of GIST from the Good Cells Perspective
February 2012 (View e-newsletter on www.GISTNews.org)
Vol. 13, No. 1
· Genetic Markers of Progression in GIST and their Significance
· Oct 1 Study Shows Promise for some CML Patients, Could There be Benefit for GIST
December 2011 (View e-newsletter on www.GISTNews.org)
Vol. 12, No. 6
· CTOS Wrapup - The LRG Among Key Presenter
· Pfizer to Open Clinical Trial for Young Patients with GIST
October 2011 (View e-newsletter on www.GISTNews.org)
Vol. 12, No. 5
· LRG To Make It's Mark on CTOS
August 2011 (View e-newsletter on www.GISTNews.org)
Vol. 12, No. 4
· Adjuvant Gleevec star of ASCO: What we learned
· Case Study: challenges of long-term therapy in GIST
· ASCO 2011: GIST Overview
· Furthering research through the NIH Pediatric GIST clinic
June 2011 (View e-newsletter on www.GISTNews.org)
Vol. 12, No. 3
· Mutational testing & survival: where we stand
· The connection between ICCs and GIST
· State of the GIST Community Part 3: What do we know about mutational testing?
April 2011 (View e-newsletter on www.GISTNews.org)
Vol. 12, No. 2
· Wildtype GIST & SDH: what to know
· Behind the walls of Brigham & Women's: Fletcher's lab
· April 2011 clinical trials update
· State of the GIST Community Part 2: What do we know about your diagnosis?
February 2011 (View e-newsletter on www.GISTNews.org)
Vol. 12, No. 1
· D842V gets its moment in the spotlight
December 2010 (View e-newsletter on www.GISTNews.org)
Vol. 11, No. 4
· Adjuvant Gleevec: To take or not to take?
October 2010 (View e-newsletter on www.GISTNews.org)
Vol. 11, No. 3
· Updates from ASCO 2010
April 2010 (View e-newsletter on www.GISTNews.org)
Vol. 11, No. 1
· Researchers collaborate at Monterrey meeting
· Updates from GI ASCO 2010
February 2010 (View e-newsletter on www.GISTNews.org)
Vol. 11, No. 1
· Bench to bedside and back again
· It’s time to consider mutational status for resistant GIST patients: KIT exons 9 & 11
· February 2010 clinical trials update
· Tasigna shows greater efficacy over Gleevec for CML: Will GIST be next?
· Synta opens phase II trial STA-9090 in GIST
December 2009 (View e-newsletter on www.GISTNews.org)
Vol. 10, No. 9
· IGF-1R: A novel GIST therapeutic target
· CTOS 2009 Reports: Adult & Pediatric GIST
· A spotlight on trials for adjuvant GIST
· December 2009 clinical trials update
October 2009 (View e-newsletter on www.GISTNews.org)
Vol. 10, No. 8
· Defining molecular mechanisms of imatinib in the treatment of GIST
· It’s time to consider mutational status for resistant GIST patients: PDGFRA Mutations
· REGISTER Study Open in Australia, New Zealand and South Korea
· October 2009 clinical trials update
August 2009 (View e-newsletter on www.GISTNews.org) View Clinical Trials Bulletin
Vol. 10, No. 7
· Researcher update in Pediatric GIST
· August 2009 clinical trials update
July 2009 GISTLink (View e-newsletter on www.GISTNews.org) View Clinical Trials Bulletin
· ASCO 2009 News
June 2009 (View e-newsletter on www.GISTNews.org) View Clinical Trials Bulletin
Vol. 10, No. 6
· Interstitial cells of Cajal: What are they and why should you care?
· June 2009 US clinical trials update
· NIH announces new program to develop therapeutics for rare and neglected diseases
May 2009 (View e-newsletter on www.GISTNews.org) View Clinical Trials Bulletin
Vol. 10, No. 5
· HSP90 inhibitors and GIST: why this target could work
· May 2009 US clinical trials update
April 2009 (View e-newsletter on www.GISTNews.org)
Vol. 10, No. 4
· GIST diagnosis: The pathologist's perspective
· April 2009 US clinical trials update
· Life Raft members share medical solutions
March 2009 (View e-newsletter on www.GISTNews.org)
Vol. 10, No. 3
· New developments in gene expression profiling
· Better monitoring for Sutent-related heart problems may be warranted
· March 2009 international clinical trials update
· Cancer in the News: CMS broadens PET scan coverage, President Obama calls out cancer
February 2009 (View e-newsletter on www.GISTNews.org)
Vol. 10, No. 2
· More front-line trials for GIST may help prevent resistance
· New LRG clinical trials database explained
· February 2009 US clinical trials update
· KIT signaling & new approaches for GIST therapy
January 2009 (View e-newsletter on www.GISTNews.org)
Vol. 10, No. 1
· Hereditary GIST Explained
· Plasma level testing: what we know, what we don't & what we hope to learn
· FDA Approves Gleevec to Prevent Recurrence in GIST
· Treatment strategies & mutational testing among key topics at CTOS 2008
· January 2009 international clinical trials update
December 2008
Vol. 9, No. 12
· The challenge of imatinib resistance in GIST
November 2008
Vol. 9, No. 11
· New treatments for D842V mutations
· November US clinical trials update
September 2008
Vol. 9, No. 9
· Routine mutational and plasma level testing: The time has come
· MSK team finds rare new mutation
· September 2008 international clinical trials update
· Gleevec receives FDA priority review as first therapy to reduce recurrence of GI stromal tumors after surgery
August 2008
Vol. 9, No. 8
· August 2008 US clinical trials update
· Infinity's IPI-504 enters phase III
· More GIST highlights from ASCO 2008
· Progression-Free Survival: Patient Benefit or Lower Standard
July 2008
Vol. 9, No. 7
· Potential new signal pathway in GIST
· July 2008 international clinical trials update
· Infinity's IPI-504 completes phase I
June 2008
Vol. 9, No. 6
· New target found for wild-type and pediatric GIST
· June 2008 US clinical trials update
· The role of CT and PET scans in the evaluation of GIST
May 2008
Vol. 9, No. 5
· Interpreting research: dilemmas facing patients and physicians
· PI3Ks: a new target in GIST and new drugs in trials
· MRIs, CTs and PET scans examined and clarified
April 2008
Vol. 9, No. 4
· Call dissects 2007 LRG study
· April 2008 US clinical trials update
· Concerns raised, FDA meets on ESAs
· The doctor is in: common patient questions answered (Part Two)
March 2008
Vol. 9, No. 3
· Special Edition: The effect of imatinib dose upon the survival of metastatic GIST patients, an LRG study
February 2008
Vol. 9, No. 2
· The doctor is in: common patient questions answered
· Suboptimal response in CML linked to Gleevec uptake into leukemia cells
· February 2008 clinical trial update
· GI Symposium offers interesting absracts
January 2008
Vol. 9, No. 1
· Molecular therapy and surgery combined in GIST
· January 2008 U.S. and international clinical trials update
December 2007
Vol. 8, No. 12
· Apoptosis: How to kill a GIST cell
· Dana-Farber study focuses on wild-type Kit and pediatric GIST
· December 2007 US & international clinical trial update
· Columbia researchers say CT scan overuse may lead to significant public health problem
· Opening of ‘Gleevec+IL2’ phase I trial at Gustave Roussy
· Kwart represents LRG at this year’s NORD conference
November 2007
Vol. 8, No. 11
· Looking for new ways to fight GIST
· November 2007 clinical trials update
· New views of receptor molecule may open doors
October 2007
Vol. 8, No. 10
· Building blocks of tumor progression
· October 2007 international clinical trials update
· Reports of good Nexavar response
· Carney-Stratakis syndrome explained
September 2007
Vol. 8, No. 9
· Pediatric GIST: an evolving concept
· NCCN task force takes strong stand in genotyping debate
· September 2007 clinical trial update
August 2007
Vol. 8, No. 8
· GIST Research Progress Report
· Highlights from ASCO 2007
· August 2007 clinical trial update
July 2007
Vol. 8, No. 7
· Looking for kinase mutations in GISTs: how, when and why?
· Highlights from ASCO 2007
· July 2007 clinical trial update
May 2007
Vol. 8, No. 5
· KIT & PDGFRA mutations in GIST: A to Z
· Clinical trial confirms Gleevec reduces recurrence
· Immunotherapy trial strives to improve Gleevec response
· Adjuvant Gleevec Q&A with Jonathan Trent and Jerry Call
· May 2007 clinical trial update
· AMN107 (Tasigna) now open at Fox Chase Cancer Center
April 2007
Vol. 8, No. 4
· Gene microarray technology yields interesting results in the laboratory
· April 2007 clinical trial update
· Novel KIT inhibitor also targets a new suspect; clinical trials to begin this year
· LRG works with medical institutions on Familial GIST study
· Simple two-gene test sorts out similar gastrointestinal cancers
March 2007
Vol. 8, No. 3
· The use of mouse models to help investigate GIST
· Immunotherapy: a new hope for GIST treatment
· Gleevec: revolutionizing GIST cancer treatment
· March 2007 clinical trial update
February 2007
Vol. 8, No. 2
· Understanding GIST survival under imatinib treatment
· Understanding drug classes
· February 2007 clnical trial update
January 2007
Vol. 8, No. 1
· Overcoming treatment resistance in GIST patients
· Questions to consider for adjuvant treatment
· January 2007 clinical trials update
December 2006
Vol. 7, No. 10
· European conferences attract GIST medical professionals
· Call comments on phase III Sutent results
· December 2006 clinical trials update
November 2006
Vol. 7, No. 9
· Connecting the Dots: Call offers perspective on GIST trends
· Researchers give update on GIST Resistance Project
· November 2006 clinical trial update
September 2006
Vol. 7, No. 8
· GIST studies receive substantial interest at ASCO '06 conference
· September 2006 clinical trial update
August 2006
Vol. 7, No. 7
· More placebo clinical trials predicted for cancer patients
· Is there a role for drug level testing
· Surgery and genotyping studies highlighted at ASCO conference
· AMG 706 will not get FDA approval for GIST
· Opinion on surgery for metastatic GIST
· Gleevec still beneficial, despite evidence of heart disease
July 2006
Vol. 7, No. 6
· Mutational testing predicts GIST treatment response
· Novartis-Schering drug vatalanib produces interesting early results
· Editorial: The time for routine mutational testing has come
· Life Raft meets with Infinity about IPI-504
· AMG706 continues testing as second line drug for Gleevec-resistant GIST patients
· ASCO reports Sutent as important drug for pediatric GIST
June 2006
Vol. 7, No. 5
· EORTC Study: Progression-free survival improves for 800 mg vs. 400 mg patients
· A continued discussion on optimizing therapy for GIST (View complete article by clicking here)
· June 2006 clinical trial update for GIST patients
· Highlights from the American Association for Cancer Research meeting
May 2006
Vol.
7, No. 4
· Understanding pediatric GIST may provide important clues
· May 2006 clinical trial update for GIST patients
March-April 2006
Vol.
7, No. 3
· Life
Raft funds 10 research
projects
· March
clinical trial update for
resistant GIST
· Optimizing
therapy for GIST: A
Discussion (View complete article by clicking here)
· Imatinib
resistance focus of intense
study
· Patient
status after four years on
Gleevec
February 2006
Vol.
7, No. 2
· Standard
treatment guidelines for
GIST
· Explosion
of GIST information raises
questions
· GIST
Q&A with Dr. Peter Reichardt
· A
roundup of clinical trials
January 2006
Vol. 7,
No. 1
· Sutent
given U.S. approval
· Challenges
ahead for the GIST community
· Infinity
launches trial of IPI-504
vs. GIST
December 2005
Vol. 6,
No. 9
· GIST
and Gleevec: 5 years of
progress
· Clinical
trial updates as of December
2005
November 2005
Vol.
6, No. 8
· Resistant
GIST may fall to new
inhibitor
· An
overview of CTOS 2005
September-October 2005
Vol.
6, No. 7
·
First strategic plan to
address treatment resistance
started
·
Life Raft members share
medical solutions
· Clinical
Trials target resistant GIST
July-August 2005
Vol.
6, No. 6
·
AMN107 + Gleevec clinical
trial opens
·
FDA fast-tracks approval
process for sutent
·
New insights to multi-drug
resistance
·
Questions and answers from
our members
June 2005
Vol.
6, No. 5
·
Advances reported at 2005
ASCO meeting
·
$2
million pledged for GIST
research
·
Sutent appears headed for
approval
·
AMG706 active vs. solid
tumors
·
PKC412 + Gleevec: stability
for some
April-May 2005
Vol.
6, No. 4
·
Beyond Gleevec: The next-era
drugs for GIST
·
Progress against GIST inches
ahead
·
Gleevec, vitamin C and
insulin slows disease
March 2005
Vol.
6, No. 3
·
Many drugs coming for
Gleevec-resistant GIST
·
PKC412 fights Gleevec-resistant
GIST
·
Druker updates stem cell
research
February 2005
Vol.
6, No. 2
·
SU11248 works, trial ends 7
months early
·
Why SU11248 works when
Gleevec fails
·
Leukemia researchers strive
for a cure
January 2005
Vol.
6, No. 1
·
Study: Gleevec levels
decrease over time
·
Fletcher tells Life Rafters
of new type of trial
·
U.S. agency puts AMG706 on
fast track
November-December 2004
Vol.
5, No. 11
·
Starting vs. actual dose
significant
·
Putting Gleevec tablets in
glycerin capsules raises
serious concerns
·
Life Raft Research Team
meets with European
researchers
·
A
Review of the posters and
papers at CTOS
·
Novartis Scientists Review
Status of Drugs in Pipeline
October 2004
Vol.
5, No. 10
·
GIST mutation top cause
Gleevec failure
·
A
survival paradigm for GIST
September 2004
Vol.
5, No. 9
·
Glivec at higher doses
combats progression
August 2004
Vol.
5, No. 8
·
More study needed to
determine optimal Gleevec
dose
·
AMGEN launches phase II
clinical-No placebo
July 2004
Vol.
5, No. 7
·
New drug holds promise for
GIST's sister cancer
·
Update on new drugs with
GIST potential
June 2004
Vol.
5, No. 6
·
Cancer experts on GIST:
Gleevec dosage level is
still unresolved at the 40th
annual ASCO meet
·
What dose Gleevec is best
·
Pathologists predict
behavior of GIST
May 2004
Vol.
5, No. 5
·
GIST patients, experts meet
at Life Fest 2004
·
Pathologists share their
data on GIST
April 2004
Vol.
5, No. 4
·
AACR reports on drugs with
GIST possibilities
·
Higher doses of Gleevec work
best for CML
March 2004
Vol.
5, No. 3
·
Pediatric GIST collaboration
advances
·
Setting the record straight
February 2004
Vol.
5, No. 2
·
Gleevec vs. GIST trial at 3
years
·
Test to predict Gleevec
response expands
January 2004
Vol.
5, No. 1
·
U.S., Germany launch
‘Gleevec combo' trial
·
Novartis told of Gleevec
tablet side effects
November-December 2003
Vol.
4, No. 11
·
Placebo use in Pfizer trial
raises fears
·
Lowering dose not advised
October 2003
Vol.
4, No. 10
·
Chicago area patients seek a
‘center of excellence'
September 2003
Vol.
4, No. 9
·
Loyola doctors focus on
STAT3 signaling
August 2003
Vol.
4, No. 8
·
Sugen offers option when
Gleevec fails
·
GIST patients see new
clinical trials
July 2003
Vol.
4, No. 7
·
Targets, targeted therapy
reports abound at AARC
·
Glivec Ok'd for GIST in
Japan, Israel
June 2003
Vol.
4, No. 6
·
Sugen drug an option if
Gleevec fails
·
Studies differ over 400 mg.
vs. 800 mg.
·
Gleevec tablets just as good
as capsules
·
Life Raft raises research
questions
·
Study: GIST can outwit
Gleevec four ways
·
Test reveals who'll respond
to Gleevec
May 2003
Vol.
4, No. 5
·
New drug outwits Gleevec
resistance
April 2003
Vol.
4, No. 4
·
Relapse survey: Is bigger
dose better?
March 2003
Vol.
4, No. 3
·
Researchers: Protein defect
linked to GIST
February 2003
Vol.
4, No. 2
·
Some observations on GIST
research and a tumor bank
January 2003
Vol.
4, No. 1
·
GIST patients help
researchers zero in on the
origins of cancer
December 2002
Vol.
3, No. 11
·
Sugen drug ‘surprisingly
effective' in early trials
·
Researchers find GIST more
common than once thought
November 2002
Vol.
3, No. 10
·
Life Raft gleens facts at
oncology meeting
·
Glivec-chemo combinations
warrant study
September 2002
Vol.
3, No. 8
·
Doctors hear of Life Raft
experience at London meet
July-August 2002
Vol.
3, No. 7
·
KIT remains the primary
target of GIST therapy
June 2002
Vol.
3, No. 6
·
UK
cost-cutting agency stalls
the use of Glivec
May 2002
Vol.
3, No. 5
·
Gleevec's effects are
lasting, researchers believe
April 2002
Vol.
3, No. 4
·
Early testing begins for new
GIST drug
February 2002
Vol.
3, No. 2
·
U.S. OK's Gleevec for GIST
January 2002
Vol.
3, No. 1
·
Gleevec on way to being No.
1 treatment for CML
November 2001
Vol.
2, No. 10
·
Novartis seeks U.S. OK to
use Gleevec on GIST
·
Glivec approved in European
Union for CML
October 2001
Vol.
2, No. 9
·
Life Raft patients report
fatigue is top side effect
September 2001
Vol.
2, No. 8
·
‘Glivec' moves closer to
European approval
July-August 2001
Vol.
2, No. 7
·
GIST researcher shares ‘our'
Gleevec experience
June 2001
Vol.
2, No. 6
·
Life Raft patients share
responses, side effects
May 2001
Vol.
2, No. 5
·
Gleevec OK'd by FDA;
effectiveness hailed
·
‘Off label' use worries
Gleevec researchers
·
Journal reports on clinical
trial patient No. 1
April 2001
Vol.
2, No. 4
·
Real Progress with real
people, thanks to the global
community
·
Survey: Gender plays role in
side effects
March 2001
Vol.
2, No. 3
·
STI571 notes from leukemia
group at OHSU
·
Novartis files globally for
approval of Glivec
February 2001
Vol.
2, No. 2
·
The fast-track story of
STI571
January 2001
Vol.
2, No. 1
·
Glivec resistance a concern;
optimism prevails
·
New NCI-sponsored clinic
trial of STI571 for GIST
*This is an attempt to help you find all the science articles in our newsletters. Be aware that some of the info will change over time.
